HIV/AIDS: Research and Palliative Care (Mar 2021)
Determinants of Drug-Induced Hepatotoxicity Among Patients with Human Immunodeficiency Virus Taking a High Dose of Rifapentine Plus Isoniazid Drugs at the All Africa Leprosy Tuberculosis Rehabilitation and Training Center in Addis Ababa, Ethiopia
Abstract
Leuel Lisanwork Arage,1 Haji Aman Deybasso,2 Delelegn Yilma Gebremichael,3 Binyam Gintamo Nuramo,4 Zelalem Negash Mekuria4 1The Ohio State University Global One Health, Addis Ababa, Ethiopia; 2Adama Hospital Medical College, Adama, Ethiopia; 3Ambo University, College of Medicine and Health Sciences, Department of Public Health, Ambo, Ethiopia; 4Addis Ababa Medical and Business College, Department of Research and Community Service, Addis Ababa, EthiopiaCorrespondence: Haji Aman Deybasso Tel +251 911386781Email [email protected]: The drugs for the treatment of latent Tuberculosis are potentially hepatotoxic and can lead to drug-induced hepatotoxicity. The current study aimed at identifying the determinants of anti-tuberculosis drug-induced hepatotoxicity among patients living with Human Immunodeficiency Virus taking Isoniazid and rifapentine at All Africa Leprosy Tuberculosis Rehabilitation and Training Center in Addis Ababa, Ethiopia.Methods: An unmatched case–control study was conducted from March, 21, to April 21, 2020, at All Africa Leprosy Tuberculosis Rehabilitation and Training Center. A total of 65 cases and 130 controls were interviewed. Data were collected using a data extraction tool from clinical reporting forms, follow-up charts, and patients’ logbooks. Binary and multiple logistic regressions were conducted to check the association between independent and dependent variables. Adjusted odds ratios and the corresponding 95% confidence intervals were estimated to assess the strength of association. P-values < 0.05 were used to declare statistical significance.Results: The prevalence of anti-TB drug-induced hepatotoxicity was 8%. Body mass index < 18.5 Kg/m2 (AOR = 5.8 [95% CI: 2.2– 8.9]), low CD4 count (AOR = 4.9 [95% CI: 1.6– 15.8]), and the presence of comorbid illnesses (AOR = 3.9 [95% CI: 1.7– 8.9]) were identified as independent predictors of drugs-induced hepatotoxicity among Human Immunodeficiency Virus positive patients taking Isoniazid and rifapentine.Conclusion: The prevalence of anti-TB drug-induced hepatotoxicity was higher compared to standard references. BMI< 18 kg/m2, low CD4 count, and comorbid illness were positively associated with anti-tuberculosis drug-induced hepatotoxicity among patients with HIV.Keywords: isoniazid and rifapentine, TPT, hepatotoxicity, HIV patients, Ethiopia
